Switch theme
Sign up to access all valuation multiples
Race Oncology Ltd is a clinical stage biopharmaceutical company with a mission to be at the heart of cancer care. Its asset, bisantrene, is a small molecule chemotherapeutic. Bisantrene has a clinical history with demonstrated therapeutic benefits in both adult and pediatric patients, a well-characterized safety profile, and compelling clinical data demonstrating an anticancer effect and less cardiotoxicity over certain anthracyclines, such as doxorubicin. It has reformulated bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on anthracycline combinations, where Race can deliver cardioprotection and enhanced anticancer activity in solid tumors.
2011
n/a
Last FY Revenue n/a
LTM EBITDA -$4.1M
$121M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Race Oncology has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$4.1M.
In the most recent fiscal year, Race Oncology achieved revenue of n/a and an EBITDA of -$12.1M.
Race Oncology expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Race Oncology valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$4.1M | XXX | -$12.1M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$4.3M | XXX | -$12.3M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$4.2M | XXX | -$9.1M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, Race Oncology's stock price is AUD 1 (or $1).
Race Oncology has current market cap of AUD 203M (or $134M), and EV of AUD 184M (or $121M).
See Race Oncology trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $121M | $134M | XXX | XXX | XXX | XXX | $-0.06 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, Race Oncology has market cap of $134M and EV of $121M.
Race Oncology's trades at n/a EV/Revenue multiple, and -15.1x EV/EBITDA.
Equity research analysts estimate Race Oncology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Race Oncology has a P/E ratio of -32.2x.
See valuation multiples for Race Oncology and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $134M | XXX | $134M | XXX | XXX | XXX |
| EV (current) | $121M | XXX | $121M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -29.7x | XXX | -15.1x | XXX | XXX | XXX |
| EV/EBIT | -28.3x | XXX | -14.7x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -32.2x | XXX | -20.3x | XXX | XXX | XXX |
| EV/FCF | -30.2x | XXX | -23.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialRace Oncology's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Race Oncology's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Race Oncology's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Race Oncology and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 330% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Race Oncology acquired XXX companies to date.
Last acquisition by Race Oncology was XXXXXXXX, XXXXX XXXXX XXXXXX . Race Oncology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Race Oncology founded? | Race Oncology was founded in 2011. |
| Where is Race Oncology headquartered? | Race Oncology is headquartered in Australia. |
| Is Race Oncology publicy listed? | Yes, Race Oncology is a public company listed on ASX. |
| What is the stock symbol of Race Oncology? | Race Oncology trades under RAC ticker. |
| When did Race Oncology go public? | Race Oncology went public in 2016. |
| Who are competitors of Race Oncology? | Similar companies to Race Oncology include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Race Oncology? | Race Oncology's current market cap is $134M |
| Is Race Oncology profitable? | Yes, Race Oncology is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Race Oncology? | Race Oncology's last 12 months EBITDA is -$4.1M. |
| What is the current EV/EBITDA multiple of Race Oncology? | Current EBITDA multiple of Race Oncology is -29.7x. |
| What is the current FCF of Race Oncology? | Race Oncology's last 12 months FCF is -$4.0M. |
| What is the current EV/FCF multiple of Race Oncology? | Current FCF multiple of Race Oncology is -30.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
